Business
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC), key assets in CStone Pipeline 2.0, have been delivered at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
About this update from Cstone Pharmaceuticals
[{"type":"text","content":"SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC), key assets in CStone Pipeline 2.0, have been delivered at the 2025 American Association for Cancer Research (AACR) Annual Meeting.","length":499,"tagName":"p"},{"type":"text","content":"Key Highlights:","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CS2011 (EGFR/HER3 bispecific antibody):","length":39,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":39,"olType":false},{"type":"text","content":"EGFR and HER3 are members of the human epidermal growth factor receptor (HER) family and are validated therapeutic targets in advanced solid tumors. EGFR overexpression drives tumor progression in approximately 70% of colorectal cancers (CRC), 60% of lung cancers, and over 90% of head and neck squamous cell carcinomas (HNSCC). Meanwhile, HER3 upregulation frequently emerges as a resistance mechanism to MAPK/PI3K inhibitors, EGFR tyrosine kinase inhibitors (TKIs), and hormone therapies. CS2011 is a bispecific antibody with high binding affinity to both EGFR and HER3. It effectively blocks downstream signaling of both targets, thereby inhibiting tumor growth on EGFR/HER3 positive tumor cells.","length":704,"tagName":"p"},{"type":"text","content":"1. CS2011 targets almost all HER family signaling except HER2 homodimers, addressing tumor heterogeneity effectively.","length":165,"tagName":"p"},{"type":"text","content":"2. CS2011 demonstrates potent binding affinity to EGFR and/or HER3 individually and enhanced dual binding affinity to EGFR and HER3 concurrently driven by avidity-based synergy.","length":225,"tagName":"p"},{"type":"text","content":"3. CS2011 inhibits tumor growth by binding to EGFR and/or HER3-positive tumor cells.","length":132,"tagName":"p"},{"type":"text","content":"4. CS2011 shows superior in vivo and in vitro ...